OM Pharma

Executive Summary

OM Pharma is a Swiss biopharmaceutical company with over 85 years of history, specializing in immune modulation for the prevention of recurrent respiratory and urinary tract infections, as well as vascular disease treatment. Its flagship product, OM-85 (Broncho-Vaxom), is a bacterial lysate immunostimulant widely used in Europe and other regions to reduce the incidence of respiratory infections. The company also has a pipeline of microbiome-based therapies and small molecules targeting recurrent UTIs and vascular conditions. OM Pharma's long-standing presence and established commercial products provide a stable revenue base, while its R&D efforts focus on expanding indications and geographic reach. Recent investments in clinical trials and regulatory submissions signal a push toward FDA approval in the US, which could unlock significant growth. The company's private status limits financial transparency, but its specialized niche and proven track record make it a resilient player in the immunology space.

Upcoming Catalysts (preview)

• Q1 2027FDA filing for OM-85 in recurrent respiratory infections40% success
• Q4 2026Phase 3 results for OM-89 in recurrent urinary tract infections50% success
• Q3 2026New partnership for vascular disease program30% success